ArticleFuture oncology (London, England)2026

Real-world outcomes after CAR T versus standard therapy in third-line or later relapsed or refractory follicular lymphoma in the United States.

Philip K Chan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.